Eli Lilly and Company, with contract manufacturer Resilience, announced a $750 million investment. This investment will expand pharmaceutical production in the United States.
It targets Resilience's facilities in the Cincinnati, Ohio region. The expansion expects to create at least 400 new jobs.
The expansion will increase manufacturing capacity for Lilly's KwikPen injectable device. This device is used for its popular diabetes and obesity medicines.
This move supports Lilly's strategy to meet surging demand for its treatments. It also aims to strengthen its domestic supply chain. Operations anticipate full functionality by early 2027.